555 related articles for article (PubMed ID: 35354425)
21. Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines.
Guo X; Liu D; Huang Y; Deng Y; Wang Y; Mao J; Zhou Y; Xiong Y; Gao X
Virol J; 2023 Apr; 20(1):64. PubMed ID: 37029389
[TBL] [Abstract][Full Text] [Related]
22. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
[TBL] [Abstract][Full Text] [Related]
23. mRNA vaccines against infectious diseases and future direction.
Aleem MT; Munir F; Shakoor A; Gao F
Int Immunopharmacol; 2024 Jun; 135():112320. PubMed ID: 38788451
[TBL] [Abstract][Full Text] [Related]
24. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.
Wei J; Hui AM
Cancer Treat Rev; 2022 Jun; 107():102405. PubMed ID: 35576777
[TBL] [Abstract][Full Text] [Related]
25. Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases.
Elkhalifa D; Rayan M; Negmeldin AT; Elhissi A; Khalil A
Biomed Pharmacother; 2022 Jan; 145():112385. PubMed ID: 34915673
[TBL] [Abstract][Full Text] [Related]
26. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo.
Cao Q; Fang H; Tian H
Biomaterials; 2024 Oct; 310():122628. PubMed ID: 38820767
[TBL] [Abstract][Full Text] [Related]
27. Development of mRNA Vaccines/Therapeutics and Their Delivery System.
Son S; Lee K
Mol Cells; 2023 Jan; 46(1):41-47. PubMed ID: 36697236
[TBL] [Abstract][Full Text] [Related]
28. Cancer mRNA vaccines: clinical advances and future opportunities.
Sayour EJ; Boczkowski D; Mitchell DA; Nair SK
Nat Rev Clin Oncol; 2024 Jul; 21(7):489-500. PubMed ID: 38760500
[TBL] [Abstract][Full Text] [Related]
29. RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?
Sandbrink JB; Shattock RJ
Front Immunol; 2020; 11():608460. PubMed ID: 33414790
[TBL] [Abstract][Full Text] [Related]
30. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine.
Muramatsu H; Lam K; Bajusz C; Laczkó D; Karikó K; Schreiner P; Martin A; Lutwyche P; Heyes J; Pardi N
Mol Ther; 2022 May; 30(5):1941-1951. PubMed ID: 35131437
[TBL] [Abstract][Full Text] [Related]
31. Innate immune mechanisms of mRNA vaccines.
Verbeke R; Hogan MJ; Loré K; Pardi N
Immunity; 2022 Nov; 55(11):1993-2005. PubMed ID: 36351374
[TBL] [Abstract][Full Text] [Related]
32. Computational design of mRNA vaccines.
Kim YA; Mousavi K; Yazdi A; Zwierzyna M; Cardinali M; Fox D; Peel T; Coller J; Aggarwal K; Maruggi G
Vaccine; 2024 Mar; 42(7):1831-1840. PubMed ID: 37479613
[TBL] [Abstract][Full Text] [Related]
33. The mRNA vaccine, a swift warhead against a moving infectious disease target.
Mir S; Mir M
Expert Rev Vaccines; 2024; 23(1):336-348. PubMed ID: 38369742
[TBL] [Abstract][Full Text] [Related]
34. Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects.
Edwards DK; Carfi A
Curr Opin Immunol; 2022 Aug; 77():102214. PubMed ID: 35671599
[TBL] [Abstract][Full Text] [Related]
35. A network analysis of COVID-19 mRNA vaccine patents.
Gaviria M; Kilic B
Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
[No Abstract] [Full Text] [Related]
36. Regulatory Considerations on the Development of mRNA Vaccines.
Naik R; Peden K
Curr Top Microbiol Immunol; 2022; 440():187-205. PubMed ID: 32638114
[TBL] [Abstract][Full Text] [Related]
37. Nucleoside-modified messenger RNA COVID-19 vaccine platform.
Roncati L; Corsi L
J Med Virol; 2021 Jul; 93(7):4054-4057. PubMed ID: 33675239
[TBL] [Abstract][Full Text] [Related]
38. Vaccines' New Era-RNA Vaccine.
Zhou W; Jiang L; Liao S; Wu F; Yang G; Hou L; Liu L; Pan X; Jia W; Zhang Y
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632102
[TBL] [Abstract][Full Text] [Related]
39. The clinical progress and challenges of mRNA vaccines.
Yu MZ; Wang NN; Zhu JQ; Lin YX
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1894. PubMed ID: 37096256
[TBL] [Abstract][Full Text] [Related]
40. Synthetic modified messenger RNA for therapeutic applications.
Gao M; Zhang Q; Feng XH; Liu J
Acta Biomater; 2021 Sep; 131():1-15. PubMed ID: 34133982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
